Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 4/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18586803 | 0.83 | IDO1 (0.38) | CES2IDO1TAS2R14PIEZO1MAPT | |
| SCHEMBL18587153 | 0.82 | IDO1 (0.37) | CES2IDO1TAS2R14PIEZO1MAPT | |
| SCHEMBL6864791 | 0.81 | CES2 (0.47) | CES2IDO1PIEZO1CYP3A4CYP2D6 | |
| SCHEMBL13437709 | 0.80 | IDO1 (0.53) | CES2IDO1CYP3A4CYP2D6DAO | |
| SCHEMBL17742275 | 0.79 | ESR1 (0.40) | CES2IDO1TAS2R14PIEZO1MAPT | |
| SCHEMBL4680952 | 0.79 | IDO1 (0.40) | CES2IDO1TAS2R14PIEZO1MAPT | |
| SCHEMBL6443956 | 0.79 | DAO (0.39) | CES2IDO1TAS2R14MAPTCYP3A4 | |
| SCHEMBL1745725 | 0.79 | MEN1 (0.45) | CES2MAPTNPSR1CYP3A4CYP2D6 | |
| SCHEMBL3120442 | 0.79 | ALDH1A1 (0.40) | CYP3A4DAOALDH1A1 | |
| SCHEMBL17477591 | 0.78 | CYP3A4 (0.35) | CES2IDO1TAS2R14PIEZO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-3174537-B1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3174537-B1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3344621-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | Lupin Limited (IN) | 2018-07-11 | — | — | EP | disclosed |
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3174537-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | Merck Sharp & Dohme Corp. (US) | 2017-06-07 | — | — | EP | disclosed |
| WO-2017037682-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016018729-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016018729-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2257524-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | CETP, MTTP, LCAT | CES2 146/4885IDO1 3994/4885TAS2R14 4438/4885 |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | CETP, MTTP, LCAT | CES2 146/4885IDO1 3994/4885TAS2R14 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.